Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

NCT06793917 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT06793917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06793917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Lead sponsor
Fujian Cancer Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
June 7, 2025
Completion date
April 1, 2029
Enrollment
269 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer